Monopar Therapeutics Inc. Common Stock (MNPR)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett-Graham tradition, I want durable earnings, honest assets, and a margin of safety. Monopar does not yet meet that test. It is a clinical-stage biopharmaceutical company with 22 employees and no reported revenue in fiscal 2023, 2024, or 2025. In fiscal 2025 it lost $13.7 million, or $1.85 per diluted share; fiscal 2024 lost $15.6 million, or $4.11 per share; fiscal 2023 lost $8.4 million. The recent trend is not reassuring: in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $5.3 million versus $2.5 million in fiscal Q2 2025. Trailing free cash flow is negative $12.2 million, a negative 2.5% FCF yield. The balance sheet shows no debt, with D/E 0.00, and FairStock's Altman Z-Score is 70.53, but that does not create earnings. At the 2026-10-13 close of $72.08, the negative P/E of -32.76 is meaningless, while P/B is 3.70, ROE is -19.50%, ROCE is -14.64%, Piotroski is 1/9, and FairStock Score is 58/100. FairStock assigns no Lynch category because of losses in each of the last four years. The pipeline—ALXN1840 and the MNPR-101 programs—may have optionality, but no competitive moat is proven without commercial success. Growth is unproven because there is no revenue. I see a speculative bet on clinical outcomes, not a Graham-style bargain.

In plain English: Monopar Therapeutics is a small company testing experimental cancer medicines; it does not report product sales. It has lost money in each of the last four years, including a $13.7 million loss in fiscal 2025, and its latest quarter loss widened from a year earlier. At $72.08 a share, the price looks expensive compared with the current numbers because there are no profits or revenue to back it up.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer